NASDAQ:ICLR - Icon Stock Price, Forecast & News

Icon trades on the NASDAQ under the ticker symbol "ICLR."

Icon Plc (NASDAQ:ICLR) announced its quarterly earnings data on Wednesday, October, 23rd. The medical research company reported $1.74 earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of $1.74. The medical research company earned $710.40 million during the quarter, compared to analysts' expectations of $709.75 million. Icon had a return on equity of 24.86% and a net margin of 13.16%. Icon's revenue for the quarter was up 8.5% compared to the same quarter last year. During the same quarter last year, the company earned $1.54 EPS. View Icon's Earnings History.

Icon is scheduled to release their next quarterly earnings announcement on Wednesday, February 19th 2020. View Earnings Estimates for Icon.

Icon issued an update on its FY20 earnings guidance on Tuesday, January, 14th. The company provided earnings per share (EPS) guidance of $7.55-7.85 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.71. The company issued revenue guidance of $2.97-3.09 billion, compared to the consensus revenue estimate of $3.03 billion.

9 brokers have issued 12-month price objectives for Icon's shares. Their forecasts range from $154.00 to $185.00. On average, they anticipate Icon's share price to reach $166.88 in the next twelve months. This suggests that the stock has a possible downside of 5.1%. View Analyst Price Targets for Icon.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Icon in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Icon.

News headlines about ICLR stock have been trending very negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Icon earned a news impact score of -3.8 on InfoTrie's scale. They also gave news stories about the medical research company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Icon.

Icon saw a increase in short interest in December. As of December 31st, there was short interest totalling 1,180,000 shares, an increase of 16.8% from the December 15th total of 1,010,000 shares. Based on an average daily trading volume, of 261,500 shares, the short-interest ratio is presently 4.5 days. Currently, 2.2% of the company's shares are sold short. View Icon's Current Options Chain.

Some companies that are related to Icon include Iqvia (IQV), Incyte (INCY), EXACT Sciences (EXAS), Charles River Laboratories Intl. (CRL), PRA Health Sciences (PRAH), Syneos Health (SYNH), Exelixis (EXEL), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Intrexon (XON), Sorrento Therapeutics (SRNE), Auxly Cannabis Group (CBWTF), STARPHARMA HOLD/S (SPHRY) and Luna Innovations (LUNA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Icon investors own include Pfizer (PFE), Gilead Sciences (GILD), CVS Health (CVS), Mastercard (MA), Procter & Gamble (PG), Post (POST), Visa (V), Johnson & Johnson (JNJ), Amgen (AMGN) and Euronet Worldwide (EEFT).

Icon's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Peregrine Capital Management LLC (0.42%), Summit Creek Advisors LLC (0.27%), LVM Capital Management Ltd. MI (0.12%), Henry James International Management Inc. (0.06%), Tealwood Asset Management Inc. (0.04%) and Welch & Forbes LLC (0.04%).

ICLR stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, RBA Wealth Management LLC, Arden Trust Co, Summit Creek Advisors LLC, Welch & Forbes LLC, Tealwood Asset Management Inc., Raymond James Trust N.A. and Somerset Trust Co.

ICLR stock was bought by a variety of institutional investors in the last quarter, including Diversified Trust Co, First National Bank of Omaha, Henry James International Management Inc., We Are One Seven LLC, LVM Capital Management Ltd. MI, Allred Capital Management LLC, Bangor Savings Bank and Lenox Wealth Advisors LLC.

Shares of ICLR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ICLR stock can currently be purchased for approximately $175.78.

Icon has a market capitalization of $9.49 billion and generates $2.60 billion in revenue each year. The medical research company earns $322.66 million in net income (profit) each year or $6.29 on an earnings per share basis. Icon employs 13,670 workers across the globe.View Additional Information About Icon.

The official website for Icon is http://www.iconplc.com/.

Icon's mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The medical research company can be reached via phone at 353-1291-2000.